636 related articles for article (PubMed ID: 15241631)
21. Applications of positron emission tomography in neuro-oncology: a clinical approach.
Demetriades AK; Almeida AC; Bhangoo RS; Barrington SF
Surgeon; 2014 Jun; 12(3):148-57. PubMed ID: 24629841
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Evaluation of Fluorine-18-Labeled L-Rhamnose Derivatives.
Zhang X; Basuli F; Shi ZD; Shah S; Shi J; Mitchell A; Lai J; Wang Z; Hammoud DA; Swenson RE
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175182
[TBL] [Abstract][Full Text] [Related]
23. New tracers beyond FDG in head and neck oncology.
Gornik G; Weber W
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):529-40. PubMed ID: 22019710
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging: what can be used today.
Jager PL; de Korte MA; Lub-de Hooge MN; van Waarde A; Koopmans KP; Perik PJ; de Vries EG
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S27-32. PubMed ID: 16361133
[TBL] [Abstract][Full Text] [Related]
25. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression.
Cai W; Zhang X; Wu Y; Chen X
J Nucl Med; 2006 Jul; 47(7):1172-80. PubMed ID: 16818952
[TBL] [Abstract][Full Text] [Related]
26. Non-peptidyl (18)F-labelled PET tracers as radioindicators for the noninvasive detection of cancer.
Wagner S; Kopka K
Recent Results Cancer Res; 2013; 187():107-32. PubMed ID: 23179879
[TBL] [Abstract][Full Text] [Related]
27. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
[TBL] [Abstract][Full Text] [Related]
29. Radiopharmaceuticals for positron emission tomography. Development of new, innovative tracers for measuring the rates of physiologic and biochemical processes.
Gatley SJ; DeGrado TR; Kornguth ML; Holden JE
Acta Radiol Suppl; 1990; 374():7-11. PubMed ID: 1966972
[TBL] [Abstract][Full Text] [Related]
30. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
31. Radiosynthesis of 1-[18F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer.
Sun T; Tang G; Tian H; Wang X; Chen X; Chen Z; Wang S
Appl Radiat Isot; 2012 Apr; 70(4):676-80. PubMed ID: 22196677
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic use of fluorinated nucleosides - progress in patents.
Bassetto M; Slusarczyk M
Pharm Pat Anal; 2018 Nov; 7(6):277-299. PubMed ID: 30657414
[TBL] [Abstract][Full Text] [Related]
33. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.
Juhász C; Dwivedi S; Kamson DO; Michelhaugh SK; Mittal S
Mol Imaging; 2014; 13():. PubMed ID: 24825818
[TBL] [Abstract][Full Text] [Related]
34. [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
Couturier O; Leost F; Campone M; Carlier T; Chatal JF; Hustinx R
Bull Cancer; 2005 Sep; 92(9):789-98. PubMed ID: 16203269
[TBL] [Abstract][Full Text] [Related]
35. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
Coenen HH; Elsinga PH; Iwata R; Kilbourn MR; Pillai MR; Rajan MG; Wagner HN; Zaknun JJ
Nucl Med Biol; 2010 Oct; 37(7):727-40. PubMed ID: 20870148
[TBL] [Abstract][Full Text] [Related]
36. PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.
Haubner R
Radiother Oncol; 2010 Sep; 96(3):280-7. PubMed ID: 20724013
[TBL] [Abstract][Full Text] [Related]
37. PET with radiolabeled aminoacid.
Crippa F; Alessi A; Serafini GL
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):151-62. PubMed ID: 22617237
[TBL] [Abstract][Full Text] [Related]
38. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.
Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071
[TBL] [Abstract][Full Text] [Related]
39. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
40. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
